Article Details

Novartis pays $150M for access to UCB's Parkinson's drug | BioPharma Dive

Retrieved on: 2021-12-02 23:19:18

Tags for this article:

Click the tags to see associated articles and topics

Novartis pays $150M for access to UCB's Parkinson's drug | BioPharma Dive. View article details on hiswai:

Excerpt

As with the protein amyloid beta in Alzheimer's, drugmakers have sought to block accumulation through injectable or intravenous monoclonal antibodies ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up